North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

North America influenza treatment market is expected to grow by 2.3% annually in the forecast period and reach USD 569.8 million by 2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment in the region.

Highlighted with 23 tables and 40 figures, this 91-page report North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Oseltamivir Phosphate

Baloxavir Marboxil

Peramivir

Zanamivir

Other Drugs

Based on Influenza Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Influenza A

Influenza B

Influenza C

Based on Administration Route, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Oral Administration

Other Administration Routes

Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Retail Pharmacy

Hospital Pharmacy

Clinics

Online Stores

Geographically, the following national/local markets are fully investigated:

U.S.

Canada

Mexico

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

AstraZeneca Plc

BioCryst Pharmaceuticals Inc.

Biondvax

Daiichi Sankyo Company

F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)

GlaxoSmithKline Plc

Mylan N.V

Natco Pharma Limited

Novartis AG

Sanofi

Seqirus

Teva Pharmaceutical Industries Limited

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AstraZeneca Plc

BioCryst Pharmaceuticals Inc.

Biondvax

Daiichi Sankyo Company

F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)

GlaxoSmithKline Plc

Mylan N.V

Natco Pharma Limited

Novartis AG

Sanofi

Seqirus

Teva Pharmaceutical Industries Limited

Table Of Content

Table Of Content

1 Introduction 5

1.1 Industry Definition and Research Scope 5

1.1.1 Industry Definition 5

1.1.2 Research Scope 6

1.2 Research Methodology 9

1.2.1 Overview of Market Research Methodology 9

1.2.2 Market Assumption 10

1.2.3 Secondary Data 10

1.2.4 Primary Data 10

1.2.5 Data Filtration and Model Design 12

1.2.6 Market Size/Share Estimation 13

1.2.7 Research Limitations 14

1.3 Executive Summary 15

2 Market Overview and Dynamics 17

2.1 Market Size and Forecast 17

2.1.1 Impact of COVID-19 on the Market 18

2.2 Major Growth Drivers 20

2.3 Market Restraints and Challenges 24

2.4 Emerging Opportunities and Market Trends 27

2.5 Porter's Fiver Forces Analysis 31

3 Segmentation of North America Market by Product Type 35

3.1 Market Overview by Product Type 35

3.2 Oseltamivir Phosphate 37

3.3 Baloxavir Marboxil 38

3.4 Peramivir 39

3.5 Zanamivir 40

3.6 Other Drugs 41

4 Segmentation of North America Market by Influenza Type 42

4.1 Market Overview by Influenza Type 42

4.2 Influenza A 44

4.3 Influenza B 45

4.4 Influenza C 46

5 Segmentation of North America Market by Administration Route 47

5.1 Market Overview by Administration Route 47

5.2 Oral Administration 49

5.3 Other Administration Routes 50

6 Segmentation of North America Market by Distribution Channel 51

6.1 Market Overview by Distribution Channel 51

6.2 Retail Pharmacy 53

6.3 Hospital Pharmacy 54

6.4 Clinics 55

6.5 Online Stores 56

7 North America Market 2019-2030 by Country 57

7.1 Overview of North America Market 57

7.2 U.S. 60

7.3 Canada 64

7.4 Mexico 66

8 Competitive Landscape 68

8.1 Overview of Key Vendors 68

8.2 New Product Launch, Partnership, Investment, and M&A 71

8.3 Company Profiles 72

AstraZeneca Plc 72

BioCryst Pharmaceuticals Inc. 74

Biondvax 75

Daiichi Sankyo Company 76

F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 77

GlaxoSmithKline Plc 78

Mylan N.V 79

Natco Pharma Limited 80

Novartis AG 81

Sanofi 82

Seqirus 83

Teva Pharmaceutical Industries Limited 84

9 Investing in North America Market: Risk Assessment and Management 85

9.1 Risk Evaluation of North America Market 85

9.2 Critical Success Factors (CSFs) 88

Related Reports and Products 91


List Of Figure

Figure 1. Research Method Flow Chart 9

Figure 2. Breakdown of Primary Research 11

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 13

Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 15

Figure 5. North America Influenza Treatment Market, 2019-2030, USD mn 17

Figure 6. Impact of COVID-19 on Business 18

Figure 7. Primary Drivers and Impact Factors of North America Influenza Treatment Market 20

Figure 8. GDP per capita in the World, 1960-2018, USD thousand 23

Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 23

Figure 10. Primary Restraints and Impact Factors of North America Influenza Treatment Market 24

Figure 11. Investment Opportunity Analysis 28

Figure 12. Porter's Fiver Forces Analysis of North America Influenza Treatment Market 31

Figure 13. Breakdown of North America Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 35

Figure 14. North America Addressable Market Cap in 2020-2030 by Product Type, Value (USD mn) and Share (%) 36

Figure 15. North America Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, USD mn 37

Figure 16. North America Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, USD mn 38

Figure 17. North America Influenza Treatment Market: Peramivir, 2019-2030, USD mn 39

Figure 18. North America Influenza Treatment Market: Zanamivir, 2019-2030, USD mn 40

Figure 19. North America Influenza Treatment Market: Other Drugs, 2019-2030, USD mn 41

Figure 20. Breakdown of North America Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 42

Figure 21. North America Addressable Market Cap in 2020-2030 by Influenza Type, Value (USD mn) and Share (%) 43

Figure 22. North America Influenza Treatment Market: Influenza A, 2019-2030, USD mn 44

Figure 23. North America Influenza Treatment Market: Influenza B, 2019-2030, USD mn 45

Figure 24. North America Influenza Treatment Market: Influenza C, 2019-2030, USD mn 46

Figure 25. Breakdown of North America Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 47

Figure 26. North America Addressable Market Cap in 2020-2030 by Administration Route, Value (USD mn) and Share (%) 48

Figure 27. North America Influenza Treatment Market: Oral Administration, 2019-2030, USD mn 49

Figure 28. North America Influenza Treatment Market: Other Administration Routes, 2019-2030, USD mn 50

Figure 29. Breakdown of North America Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 51

Figure 30. North America Addressable Market Cap in 2020-2030 by Distribution Channel, Value (USD mn) and Share (%) 52

Figure 31. North America Influenza Treatment Market: Retail Pharmacy, 2019-2030, USD mn 53

Figure 32. North America Influenza Treatment Market: Hospital Pharmacy, 2019-2030, USD mn 54

Figure 33. North America Influenza Treatment Market: Clinics, 2019-2030, USD mn 55

Figure 34. North America Influenza Treatment Market: Online Stores, 2019-2030, USD mn 56

Figure 35. Breakdown of North America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 58

Figure 36. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value (USD mn) and Share (%) 59

Figure 37. U.S. Influenza Treatment Market, 2019-2030, USD mn 61

Figure 38. Canada Influenza Treatment Market, 2019-2030, USD mn 64

Figure 39. Influenza Treatment Market in Mexico, 2015-2030, USD mn 66

Figure 40. Growth Stage of North America Influenza Treatment Industry over the Forecast Period 68


List Of Table

Table 1. Snapshot of North America Influenza Treatment Market, 2019-2030 16

Table 2. Main Product Trends and Market Opportunities in North America Influenza Treatment Market 27

Table 3. North America Influenza Treatment Market by Product Type, 2019-2030, USD mn 35

Table 4. North America Influenza Treatment Market by Influenza Type, 2019-2030, USD mn 42

Table 5. North America Influenza Treatment Market by Administration Route, 2019-2030, USD mn 47

Table 6. North America Influenza Treatment Market by Distribution Channel, 2019-2030, USD mn 51

Table 7. North America Influenza Treatment Market by Country, 2019-2030, USD mn 58

Table 8. U.S. Influenza Treatment Market by Product Type, 2019-2030, USD mn 62

Table 9. U.S. Influenza Treatment Market by Administration Route, 2019-2030, USD mn 62

Table 10. U.S. Influenza Treatment Market by Distribution Channel, 2019-2030, USD mn 62

Table 11. Canada Influenza Treatment Market by Product Type, 2019-2030, USD mn 65

Table 12. Canada Influenza Treatment Market by Administration Route, 2019-2030, USD mn 65

Table 13. Canada Influenza Treatment Market by Distribution Channel, 2019-2030, USD mn 65

Table 14. Mexico Influenza Treatment Market by Product Type, 2019-2030, USD mn 67

Table 15. Mexico Influenza Treatment Market by Administration Route, 2019-2030, USD mn 67

Table 16. Mexico Influenza Treatment Market by Distribution Channel, 2019-2030, USD mn 67

Table 17. AstraZeneca Plc: Company Snapshot 72

Table 18. AstraZeneca Plc: Business Segmentation 72

Table 19. AstraZeneca Plc: Product Portfolio 73

Table 20. AstraZeneca Plc: Revenue, 2016-2018, USD mn 73

Table 21. AstraZeneca Plc: Recent Developments 73

Table 22. Risk Evaluation for Investing in North America Market, 2019-2030 86

Table 23. Critical Success Factors and Key Takeaways 89

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

408564 Reports in repository
150+ Consulting project
100+ Analysts
8000+ Client Queries in 2022